BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance by Next Generation Sequencing
Ordering Recommendation

Order only for patients with an established diagnosis of a BCR-ABL1 positive leukemia. This test is used to determine if a mutation is present that would interfere with response to TKI therapy in Philadelphia chromosome positive (Ph+) lymphoblastic leukemia or chronic myelogenous leukemia (CML). The test detects all common mutations, including T315I. For initial BCR-ABL1 testing, refer to BCR-ABL1, Qualitative with Reflex to BCR-ABL1 Quantitative (2005010).

Massively Parallel Sequencing
10-12 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Lavendar (EDTA) or bone marrow (EDTA). 
Specimen Preparation
Transport 5 mL whole blood or 3 mL bone marrow. (Min: 1 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Serum or plasma. Specimens collected in anticoagulants other than EDTA. Frozen Specimens. Clotted or serverely hemolyzed specimens. 
Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable 
Reference Interval
Interpretive Data
Refer to report

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

For specimens having no t(9;22) fusion, this test will be canceled and the ABL1 Amplification Confirmation test will be ordered.
CPT Code(s)
Component Test Code*Component Chart NameLOINC
2008421BCR-ABL1 Mutation by NGS Source31208-2
2008422BCR-ABL1 Mutation by NGS Result55135-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • ABL Mutation (BCR-ABL1 Kinase Domain Mutation Analysis)
  • ABL1 Mutation Analysis for Imatinib (BCR-ABL1 Kinase Domain Mutation Analysis)
  • BCR-ABL1 Domain Mutation Analysis
  • BCR-ABL1 Mutation (BCR-ABL1 Domain Mutation Analysis)
  • Gleevec Resistance Mutation Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)
  • Imatinib Mesylate Resistance Analysis (BCR-ABL1 Kinase Domain Mutation)
  • Imatinib Resistance Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)
  • TKI Therapy Resistance